Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK

被引：25

作者：

Shields, Adrian M. ^{[1
]}

Anantharachagan, Ariharan ^{[2
]}

Arumugakani, Gururaj ^{[3
]}

Baker, Kenneth ^{[4
,5
]}

Bahal, Sameer ^{[6
]}

Baxendale, Helen ^{[7
]}

Bermingham, William ^{[8
]}

Bhole, Malini ^{[9
]}

Boules, Evon ^{[10
]}

Bright, Philip ^{[11
]}

Chopra, Charu ^{[12
]}

Cliffe, Lucy ^{[13
]}

Cleave, Betsy ^{[13
]}

Dempster, John ^{[14
]}

Devlin, Lisa ^{[15
]}

Dhalla, Fatima ^{[16
]}

Diwakar, Lavanya ^{[17
]}

Drewe, Elizabeth ^{[13
]}

Duncan, Christopher ^{[18
]}

Dziadzio, Magdalena ^{[19
]}

Elcombe, Suzanne ^{[20
]}

Elkhalifa, Shuayb ^{[21
]}

Gennery, Andrew ^{[22
,23
]}

Ghanta, Harichandrana ^{[24
]}

Goddard, Sarah ^{[17
]}

Grigoriadou, Sofia ^{[25
]}

Hackett, Scott ^{[26
]}

Hayman, Grant ^{[27
]}

Herriot, Richard ^{[28
]}

Herwadkar, Archana ^{[21
]}

Huissoon, Aarnoud ^{[8
]}

Jain, Rashmi ^{[16
]}

Jolles, Stephen ^{[29
]}

Johnston, Sarah ^{[11
]}

Khan, Sujoy ^{[30
]}

Laffan, James ^{[27
]}

Lane, Peter ^{[1
]}

Leeman, Lucy ^{[31
]}

Lowe, David M. ^{[6
,32
]}

Mahabir, Shanti ^{[33
]}

Mac Lochlainn, Dylan James ^{[16
]}

McDermott, Elizabeth ^{[13
]}

Misbah, Siraj ^{[16
]}

Moghaddas, Fiona ^{[11
]}

Morsi, Hadeil ^{[16
]}

Murng, Sai ^{[27
]}

Noorani, Sadia ^{[34
]}

O'Brien, Rachael ^{[35
]}

Patel, Smita ^{[16
]}

Price, Arthur ^{[33
]}

机构：

[1] Univ Birmingham, Inst Immunol & Immunotherapy, Clin Immunol Serv, Birmingham, W Midlands, England

[2] Lancashire Teaching Hosp NHS Fdn Trust, Preston, Lancs, England

[3] Leeds Teaching Hosp NHS Trust, Dept Clin Immunol & Allergy, St James Univ Hosp, Leeds, W Yorkshire, England

[4] Newcastle Univ, NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England

[5] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England

[6] Royal Free London NHS Fdn Trust, Dept Immunol, London, England

[7] Royal Papworth NHS Fdn Trust, Cambridge, England

[8] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[9] Dudley Grp NHS Fdn Trust, Birmingham, W Midlands, England

[10] Sheffield Teaching Hosp NHS Fdn Trust, Clin Immunol & Allergy Dept, Sheffield, S Yorkshire, England

[11] North Bristol NHS Trust, Clin Immunol, Bristol, Avon, England

[12] Royal Infirm Edinburgh NHS Trust, Dept Haematol & Immunol, NHS Lothian, Edinburgh, Midlothian, Scotland

[13] Nottingham Univ Hosp NHS Trust, Clin Immunol & Allergy Dept, Nottingham, England

[14] Univ Coll London Hosp, Specialist Allergy & Clin Immunol, London, England

[15] Royal Hosp, Reg Immunol Serv, Belfast, Antrim, North Ireland

[16] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Immunol, Oxford, England

[17] Royal Stoke Hosp, Dept Immunol, Stoke On Trent, Staffs, England

[18] Newcastle Univ, Translat & Clin Res Inst, Immun & Inflammat Theme, Newcastle Upon Tyne, Tyne & Wear, England

[19] UCL, Ear Inst, London, England

[20] Newcastle Upon Tyne Hosp NHS Fdn Trust, Royal Victoria Infirm, Reg Dept Clin Immunol & Allergy, Newcastle Upon Tyne, Tyne & Wear, England

[21] Salford Royal NHS Fdn Trust, Immunol Dept, Manchester, Lancs, England

[22] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England

[23] Great North Children S Hosp, Paediat Stem Cell Transplant Unit, Newcastle Upon Tyne, Tyne & Wear, England

[24] Univ Southampton, Univ Hosp Southampton NHS Trust, Dept Allergy & Clin Immunol, Southampton, Hants, England

[25] Barts Hlth NHS Trust, Immunol Dept, Royal London Hosp, London, England

[26] Univ Hosp Birmingham, Paediat Immunol Dept, Birmingham, W Midlands, England

[27] Epsom & St Helier Univ Hosp NHS Trust, Clin Immunol Serv, South West London Immunodeficiency Ctr, London, England

[28] Aberdeen Royal Infirm, Immunol Dept, Aberdeen, Scotland

[29] Univ Hosp Wales, Immunodeficiency Ctr Wales, Heath Pk, Cardiff, Wales

[30] Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England

[31] Univ Hosp Plymouth NHS Trust, Plymouth, Devon, England

[32] UCL, Inst Immun & Transplantat, London, England

[33] Leicester Royal Infirm, Clin Immunol & Allergy Dept, Leicester, Leics, England

[34] Sandwell & West Birmingham Hosp NHS Trust, Clin Immunol Dept, Birmingham, W Midlands, England

[35] Frimley Pk Hosp, Dept Clin Immunol, Frimley, Surrey, England

[36] NHS Greater Glasgow & Clyde, Clin Immunol Serv, Glasgow, Lanark, Scotland

来源：

CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2022年 / 209卷 / 03期

关键词：

COVID-19; SARS-CoV-2; hypogammaglobulinemia; inborn errors of immunity; primary immunodeficiencies; secondary immunodeficiencies; lymphopenia; COVID-19; IMMUNITY;

D O I：

10.1093/cei/uxac008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In March 2020, the United Kingdom Primary Immunodeficiency Network (UKPIN) established a registry of cases to collate the outcomes of individuals with PID and SID following SARS-CoV-2 infection and treatment. A total of 310 cases of SARS-CoV-2 infection in individuals with PID or SID have now been reported in the UK. The overall mortality within the cohort was 17.7% (n = 55/310). Individuals with CVID demonstrated an infection fatality rate (IFR) of 18.3% (n = 17/93), individuals with PID receiving IgRT had an IFR of 16.3% (n = 26/159) and individuals with SID, an IFR of 27.2% (n = 25/92). Individuals with PID and SID had higher inpatient mortality and died at a younger age than the general population. Increasing age, low pre-SARS-CoV-2 infection lymphocyte count and the presence of common co-morbidities increased the risk of mortality in PID. Access to specific COVID-19 treatments in this cohort was limited: only 22.9% (n = 33/144) of patients admitted to the hospital received dexamethasone, remdesivir, an anti-SARS-CoV-2 antibody-based therapeutic (e.g. REGN-COV2 or convalescent plasma) or tocilizumab as a monotherapy or in combination. Dexamethasone, remdesivir, and anti-SARS-CoV-2 antibody-based therapeutics appeared efficacious in PID and SID. Compared to the general population, individuals with PID or SID are at high risk of mortality following SARS-CoV-2 infection. Increasing age, low baseline lymphocyte count, and the presence of co-morbidities are additional risk factors for poor outcome in this cohort. Individuals with immunodeficiency are at increased risk of severe infection. This study looks at outcomes following SARS-CoV-2 infection in 310 patients with primary or secondary immunodeficiency in the United Kingdom and finds significantly elevated mortality in both cohorts compared to the general population. Increasing age, pre-existing lymphopenia and other co-morbidities are identified as additional risk factors for death from COVID-19 in this cohort.

引用

页码：247 / 258

页数：12

共 50 条

[41] Subacute thyroiditis following Sars-CoV-2 infection
Khalil, M.
Ali, E.
Algethamia, A.
McGowan, A.
IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 (SUPPL 4) : 111 - 112
[42] Acute Pancreatitis Following SARS-CoV-2 Infection
Khan, Zarak Hassan
Odabasic, Stefan
Mukhtar, Kashif
Roman, George
Haq, Khwaja F.
Chishti, Shania
Jaiyeoba, Charles
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S748 - S748
[43] Lung donation following SARS-CoV-2 infection
Querrey, Melissa
Kurihara, Chitaru
Manerikar, Adwaiy
Garza-Castillon, Rafael
Lysne, Jeffrey
Tomic, Rade
Budinger, G. R. Scott
Kim, Samuel
Lung, Kalvin
Yeldandi, Anjana
Bharat, Ankit
AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (12) : 4073 - 4078
[44] Optic neuritis following SARS-CoV-2 infection
Mónica Saray Rodríguez-Rodríguez
Rosa María Romero-Castro
Claudia Alvarado-de la Barrera
María Gabriela González-Cannata
Ana Karen García-Morales
Santiago Ávila-Ríos
Journal of NeuroVirology, 2021, 27 : 359 - 363
[45] Perinatal Transmission and Outcomes of SARS-CoV-2 Infection
Charan Kumar
J. P. Soni
Vishnu Kumar Goyal
Vijaya Lakshmi Nag
Pradeep Singh Rathore
Akash Sharma
Indian Journal of Pediatrics, 2022, 89 : 1123 - 1125
[46] Perinatal Transmission and Outcomes of SARS-CoV-2 Infection
Kumar, Charan
Soni, J. P.
Goyal, Vishnu Kumar
Nag, Vijaya Lakshmi
Rathore, Pradeep Singh
Sharma, Akash
INDIAN JOURNAL OF PEDIATRICS, 2022, 89 (11): : 1123 - 1125
[47] Response to 'Multimorbidity and SARS-CoV-2 infection in UK biobank'
Roy, Abhipsha Sur
Joshi, Amol
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (05) : 969 - 969
[48] SARS-CoV-2 Variant Pathogenesis Following Primary Infection and Reinfection in Syrian Hamsters
Plunkard, Jessica
Mulka, Kathleen
Zhou, Ruifeng
Tarwater, Patrick
Zhong, William
Lowman, Margaret
Wong, Amanda
Pekosz, Andrew
Villano, Jason
MBIO, 2023, 14 (02):
[49] A prospective cohort study of pregnancy outcomes following antepartum infection with SARS-CoV-2
Doss, James D.
Diveley, Emily
Zhang, Fan
Scheffer, Amy
Huang, Ruizhi
Jackson, Daniel
Raghuraman, Nandini
Carter, Ebony B.
Mysorekar, Indira U.
Kelly, Jeannie C.
PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH, 2024, 37
[50] Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer
Naranbhai, Vivek
St Denis, Kerri J.
Lam, Evan C.
Ofoman, Onosereme
Garcia-Beltran, Wilfredo F.
Mairena, Cristhian B.
Bhan, Atul K.
Gainor, Justin F.
Balazs, Alejandro B.
Iafrate, A. John
CANCER CELL, 2022, 40 (01) : 103 - +

← 1 2 3 4 5 →